Centessa Pharmaceuticals (CNTA)

• Market cap: $2.97B
• 1 day: 1.47%
• 5 days: 21.06%
• 1 month: 22.6%
• 3 months: 75.63%
• 6 months: 28.66%
• Year to date: 26.46%
• 1 year: 34.45%
• 5 years: 1.75%
• 10 years: 1.75%
• Sector: Healthcare
• Industry: Biotechnology

About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

Employees: 98

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

322% more call options, than puts

Call options by funds: $8.54M | Put options by funds: $2.02M

32% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 34

1.27% less ownership

Funds ownership: 93.79% [Q1] → 92.52% (-1.27%) [Q2]

9% less funds holding

Funds holding: 129 [Q1] → 117 (-12) [Q2]

10% less capital invested

Capital invested by funds: $1.8B [Q1] → $1.62B (-$174M) [Q2]

29% less funds holding in top 10

Funds holding in top 10: 14 [Q1] → 10 (-4) [Q2]

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30
• Avg. target: $30
• High target: $31

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Benjamin Burnett	$31	Overweight Initiated	3 Sep 2025
Chardan Capital Rudy Li	$30	Buy Maintained	12 Aug 2025
Truist Securities Danielle Brill	$30	Buy Initiated	21 Jul 2025